GLRX2 and colorectal adenocarcinoma: Further analysis of the expression of Grx2 protein in patients with colorectal adenocarcinoma revealed that 85% of patients with stage I, 31% of patients with stage II, and around 48% of patients with stage III exhibit high levels of Grx2 expression.